RC
YARW

Rangeley Capital’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Rangeley Capital’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.5K Buy
2,361
+361
+18% +$10.5K 0.07% 126
2025
Q4 		$58K Buy
2,000
+1,000
+100% +$20.1K 0.05% 113
2025
Q3 		$16.8K Buy
+1,000
New +$32.7K 0.01% 127

Other funds holding YARW

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rangeley Capital's YARW Position: Q1 2026 in Review

Rangeley Capital increased its Yarrow Bioscience, Inc. Common Stock (YARW) stake by 18% in Q1 2026, buying an estimated $10.5K and bringing the position to 2,361 shares worth $70.5K. The position accounts for 0.07% of the portfolio, ranked #126.

Rangeley Capital first reported a position in YARW in Q3 2025 and has held it in 3 quarters since. 42 funds tracked by Wall St. Rank hold YARW as of Q1 2026.

  • Rangeley Capital held 2,361 shares of Yarrow Bioscience, Inc. Common Stock worth $70.5K as of Q1 2026.
  • Rangeley Capital bought 361 Yarrow Bioscience, Inc. Common Stock shares in Q1 2026, an estimated $10.5K.
  • Yarrow Bioscience, Inc. Common Stock made up 0.07% of Rangeley Capital's portfolio in Q1 2026, its #126 holding.
  • Rangeley Capital first reported a position in Yarrow Bioscience, Inc. Common Stock in Q3 2025 and has held it in 3 quarters since.
  • 42 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.